EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

简称 EUR J PHARM BIOPHARM ·NETHERLANDS ·出版周期 Bimonthly ·年均收录 251 篇

4.3

最新影响因子

4.60%

自引率

66%

投稿难度

平均3.0个月来源Elsevie...

审稿周期

期刊简介

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS是一本专注于药剂学与生物药剂学领域的国际学术期刊，其ISSN号为0939-6411。该杂志由荷兰的Elsevier出版社出版，出版地为阿姆斯特丹，出版周期为月刊。根据最新数据，其影响因子在药剂学领域处于中等偏上水平，具体数值需参考每年更新的Journal Citation Reports。该期刊为非开放获取（非OA）期刊，但部分文章可选择开放获取模式。它被SCI数据库收录，并且在中科院分区中通常位于医学或药学大类的三区或四区，具体分区需根据年度调整确认。该杂志的发文特点集中于药物递送系统、制剂技术、生物药剂学、药物稳定性及药代动力学等研究方向，尤其注重创新性制剂技术与临床应用的结合。其稿件质量较高，审稿流程严格，但作为Elsevier旗下期刊，可能存在较高的出版费用风险，尤其是开放获取选项。总体而言，该期刊在药剂学领域具有一定学术影响力，适合从事相关研究的学者投稿或参考。

影响因子趋势

近期发表

Improved oral bioavailability of dihydromyricetin using β-cyclodextrin-grafted chitosan/tocopheryl polyethylene glycol succinate nano-delivery system: preparation, characterization, in-vitro evaluation and pharmacokinetics 2026-08-24

PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs 2026-09-02

Enhancing itraconazole Strat-M membrane absorption via biodegradable mixed micelles with platelet-like nanodomains 2026-09-13

Autophagy-mediated amplification of ferroptosis via a curcumin-loaded metal-enzyme nanoplatform for synergistic tumor therapy 2026-09-06

Towards macrophage-oriented Antituberculosis therapy: nanohydrogel and liposomal delivery of rifampicin–berberine Co-nanocrystals for enhanced intracellular Antituberculosis activity 2026-08-18

Targeted topical delivery of Ruxolitinib-Loaded nanoemulgel for potential management of Atopic Dermatitis: An integrated in silico, in vitro, and in vivo approach 2026-08-21

A carrier-free self-assembled mangiferin hydrogel as a dual-functional oral delivery system for baicalin against acetaminophen-induced acute liver injury 2026-08-26

Targeting the choroidal neovascularization microenvironment: new perspectives in nanotherapeutic strategies 2026-09-15

Development and evaluation of a virus-like particle PEDV vaccine based on MS2 bacteriophage 2026-08-28

Rebamipide nanosuspension loaded in-situ gel: A promising strategy to improve ocular delivery and treatment of dry eye disease 2026-09-01